A startup… has churned out 20,000 doses of [psilocybin], and is making more
Its scientific advisory board includes Tom Insel, the former director of the National Institutes of Mental Health.
While most of the research is being led by universities and non-profit research institutions, Compass, a for-profit company founded in 2016, sees itself as helping to fill in the gaps … For the trial, which is set to begin within a month, Compass is enrolling 216 patients across more than a dozen research sites … it has made two 250-gram batches of psilocybin, the equivalent of 20,000 doses of 25 mg of the drug. Although some of that will be tested for stability, the rest has been shaped into capsules. Those will soon be shipped to a handful of sites in Europe and North America, where Compass plans to use the psilocybin in clinical trials.
Original Article (Thisisinsider):
A startup… has churned out 20,000 doses of [psilocybin], and is making more
Artwork Fair Use: Materialscientist [Public domain]
